Identification of Inhibitors against p90 Ribosomal S6 Kinase 2 (RSK2) through Structure-Based Virtual Screening with the Inhibitor-Constrained Refined Homology Model

Citations Over TimeTop 25% of 2011 papers

Abstract

P90 ribosomal S6 kinase 2 (RSK2), which was shown to be overexpressed in human cancers, is a serine/threonine kinase and a potential target for cancer treatment. RSK2 comprises two terminal kinase domains (NTKD and CTKD) that can be inhibited by binding with different types of inhibitors at the ATP binding sites. In the absence of a crystal structure of RSK2, we constructed a model for the 3D structure of the RSK2 NTKD by homology modeling and stepwise constrained refinement with the reported inhibitors using a molecular docking method. Structure-based virtual screening was subsequently performed against a library containing commercially available compounds using the refined model. This resulted in the identification of seven novel RSK2 inhibitors with IC₅₀ values ranging from 2.4 to 14.45 μM.

Related Papers

• → IKKβ inhibitors identification part I: Homology model assisted structure based virtual screening(2009)34 cited
• → Structure-based virtual screening for identification of novel 11β-HSD1 inhibitors(2008)36 cited
• → Approaches to Virtual Screening and Screening Library Selection(2013)8 cited
• Discovery of Potential Antitubercular Activity in on-AntibioticsThrough Virtual Screening(2015)
• Virtual screening : Computer aided drug design(2021)